(Sharecast News) - TheraCryf said on Monday that its lead Ox-1 receptor antagonist programme for addiction had advanced to final toxicology studies, keeping the biotech group on track to begin human clinical trials by the end of 2026.
The AIM-traded company confirmed completion of preclinical dose range finding studies, a key...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE